<abstract xml:lang="en" xmlns="http://www.w3.org/1999/xhtml"><p>Future cancer therapies will be molecular cures. They will correct, block or destroy cancer cells by targeting molecular changes that lead to carcinogenesis. Destroying cancer cells can be done using oncolytic viruses. By blocking antibody mediated neutralization of oncolytic viruses, Herpes simplex virus type 1 glycoproteins E and I could be used in the adjuvant treatment of cancer for improving the chances of oncolytic viruses to kill cancer cells in vivo.</p></abstract>

Future cancer therapies will be molecular cures. They will correct, block or destroy cancer cells by targeting molecular changes that lead to carcinogenesis. Destroying cancer cells can be done using oncolytic viruses. By blocking antibody mediated neutralization of oncolytic viruses, Herpes simplex virus type 1 glycoproteins E and I could be used in the adjuvant treatment of cancer for improving the chances of oncolytic viruses to kill cancer cells in vivo.

Development of a selective biopharmaceutical from Herpes simplex virus type 1 glycoproteins E and I for blocking antibody mediated neutralization of oncolytic viruses

»Rhoen Klinikum AG« Hospital, 97616 Bad Neustadt ad Saale, Germany

Acta Pharmaceutica

Future cancer therapies will be molecular cures. They will correct, block or destroy cancer cells by targeting molecular changes that lead to carcinogenesis....

Development of a selective biopharmaceutical from Herpes simplex virus type 1 glycoproteins E and I for blocking antibody mediated neutralization of oncolytic viruses

Publié en ligne: 17 déc. 2010

Pages: 407 - 413

DOI: https://doi.org/10.2478/v10007-010-0039-2

Mots clés
terapija karcinoma, glikoproteini E i I, Herpes simplex virusa tipa 1, neutralizacija onkolitskih virusa posredovana antitijelima

This content is open access.

Development of a selective biopharmaceutical from Herpes simplex virus type 1 glycoproteins E and I for blocking antibody mediated neutralization of oncolytic viruses

Publié en ligne: 17 déc. 2010

Pages: 407 - 413

DOI: https://doi.org/10.2478/v10007-010-0039-2

Mots clésterapija karcinoma, glikoproteini E i I, Herpes simplex virusa tipa 1, neutralizacija onkolitskih virusa posredovana antitijelima

This content is open access.

Mots clés
terapija karcinoma, glikoproteini E i I, Herpes simplex virusa tipa 1, neutralizacija onkolitskih virusa posredovana antitijelima